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B cells mediate multiple functions that influence
immune and inflammatory responses. In this study,
T cell-mediated inflammation was exaggerated in
CD19-deficient (Cd19/) mice and wild-type mice
depleted of CD20+ B cells, whereas inflammation
was substantially reduced in mice with hyperactive
Bcells asa result ofCD19overexpression (hCD19Tg).
These inflammatory responses were negatively regu-
lated by a unique CD1dhiCD5+ B cell subset that was
absent in Cd19/mice, represented only 1%–2% of
spleen B220+ cells in wild-type mice, but was
expanded to10%of spleen B220+ cells in hCD19Tg
mice. Adoptive transfer of these CD1dhiCD5+ B cells
normalized inflammation in wild-type mice depleted
of CD20+ B cells and in Cd19/ mice. Remarkably,
IL-10 production was restricted to this CD1dhiCD5+
B cell subset, with IL-10 production diminished in
Cd19/ mice, yet increased in hCD19Tg mice.
Thereby, CD1dhiCD5+ B cells represent a unique sub-
set of potent regulatory B cells.
INTRODUCTION
B cells play a central role in humoral immunity, but they also reg-
ulate CD4+ T cell responses to foreign and self-antigens (Bouaziz
et al., 2007; Xiu et al., 2008), function as antigen-presenting cells
(Constant et al., 1995), producecytokines (Harriset al., 2000), pro-
vide costimulatory signals (Linton et al., 2003), and promote naive
CD4+ T cell differentiation into T helper 1 (Th1) or Th2 subsets
(Harris et al., 2000). Abnormal B cell function can also drive the
development of autoimmunity (Sato et al., 1996). B cells play pro-
tective roles as well because both B cell-deficient and CD19-
deficient (Cd19/) mice develop a severe nonremitting form of
experimental autoimmune encephalomyelitis (EAE), a model of
humanmultiple sclerosis (Fillatreau et al., 2002; Matsushita et al.,
2006). In addition, B cells play a protective role during T cell-me-
diated inflammation because Cd19/ mice have augmented
contact hypersensitivity (CHS) responses (Watanabe et al., 2007).
CHS is an inflammatory immune reaction that is mediated by T
cells in sensitized individuals after subsequent contact with the
sensitizing antigen. During CHS sensitization, skin antigen-pre-senting Langerhans cells migrate to draining lymph nodes and
prime antigen-specific T cells (Kripke et al., 1990). Subsequent
antigen challenge at a separate skin site results in cutaneous
infiltration of antigen-primed T cells and in edema or spongiosis
that peaks 24–48 hr after challenge and then decreases (Wang
et al., 2000). Although antigen-specific IgM production by perito-
neal B-1 cells is important during CHS initiation (Itakura et al.,
2005), this does not explain enhanced inflammation in Cd19/
mice because they are B-1a cell-deficient and generate modest
responses to most transmembrane signals and antigens (Sato
et al., 1995).
B cell deficiency delays the emergence of regulatory T cells
and interleukin-10 (IL-10) production in the central nervous sys-
tem (CNS) during EAE (Mann et al., 2007). Furthermore, IL-10
produced by B cells can downregulate autoimmune disease in
EAE (Fillatreau et al., 2002), collagen-induced arthritis (Mauri
et al., 2003), and inflammatory bowel disease (Mizoguchi et al.,
2002). IL-10-deficient (Il10/) mice also have enhanced CHS
responses (Berg et al., 1995). Neutralizing IL-10 by monoclonal
antibody (mAb) treatment also enhances CHS responses,
whereas systemic IL-10 administration reduces CHS responses
(Ferguson et al., 1994; Schwarz et al., 1994). IL-10 is secreted by
multiple cell types, including T cells, monocytes, macrophages,
mast cells, eosinophils, and keratinocytes, and can suppress
both Th1 and Th2 polarization and inhibit macrophage antigen
presentation and proinflammatory cytokine production (Asadul-
lah et al., 2003). Thus, B cells and IL-10 play important inhibitory
roles during T cell-mediated inflammatory responses.
The generation of regulatory B cells has been reported in
mouse models of chronic inflammation, although their existence
in normal mice remains unknown (Mizoguchi and Bhan, 2006).
Furthermore, it is unknown whether multiple B cell populations
or a distinct B cell subset regulates inflammatory responses,
whether regulatory B cells produce IL-10 or other cytokines
directly, or whether regulatory B cells have potent activities
in vivo. Therefore, the importance of B cells during T cell-medi-
ated inflammationwasexaminedwithCHS responses asamodel
for inflammation in Cd19/ and human CD19 transgenic
(hCD19Tg) mice and in wild-type (WT) mice with intact immune
systems that were depleted of B cells in vivo (Uchida et al.,
2004a). CHS was chosen as a model because a balance
between B cells and dendritic cells regulates CD4+ T cell expan-
sion in response to antigens in vivo (Bouaziz et al., 2007; Xiu et al.,
2008) but skin Langerhans cells are the exclusive antigen-pre-
senting cells during CHS (Bursch et al., 2007). Thereby, usingImmunity 28, 639–650, May 2008 ª2008 Elsevier Inc. 639
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Unique CD1dhiCD5+ Regulatory B Cell SubsetCHS as a model minimized the potential stimulatory roles for B
cells during immune responses. This allowed the identification
of a potent regulatory B cell subset identified by IL-10 production
and a unique CD1dhiCD5+ phenotype. These rare CD1dhiCD5+ B
cells negatively regulated antigen-specific T cell-dependent in-
flammation during CHS responses in vivo.
RESULTS
Mice with Altered B Cells Differentially
Regulate Inflammation
To assess T cell-mediated inflammation responses in mice with
altered B cell signaling, Cd19/, hCD19Tg, and WT mice were
sensitized and challenged with 4-ethyoxymethylene-2-phenyl-
oxazoline-5-one (oxazolone). B cells from hCD19Tg mice are
hyperresponsive to transmembrane signals, proliferate more to
mitogens, generate elevated humoral immune responses to T
dependent antigens, and spontaneously produce IgG autoanti-
bodies as they age (Inaoki et al., 1997). Thus, CD19 functions
as a general ‘‘rheostat’’ that defines signaling thresholds critical
for expansion of the peripheral B cell pool (Tedder, 1998). In WT
mice, ear inflammation peaked at 24 hr after challenge and then
decreased gradually (Figure 1A). Ear swelling was significantly
diminished in hCD19Tgmice comparedwithWTmice throughout
Figure 1. B Cell Regulation of T Cell-Medi-
ated Inflammatory Responses
CHS responses in (A) WT, hCD19Tg, and Cd19/
mice, (B) hCD19Tgmice treated with human CD19
or control mAb 7 days before or 2 days after initial
oxazolone sensitization, and (C)WT or (D)Cd19/
mice treated with CD20 or control mAb 7 days be-
fore or 2 days after first sensitization with oxazo-
lone. Increased ear thickness was measured
before and after oxazolone challenge. Values
represent means (± SEM) from R four mice per
group. Horizontal dashed lines represent the aver-
age increase in ear thickness at 48 hr after oxazo-
lone challenge in WT mice. Significant differences
between sample means are indicated; *, p < 0.05;
**, p < 0.01. Similar results were obtained in at least
two independent experiments.
the observation period (39% ± 13%,
48 hr, p < 0.05). By contrast, ear swelling
was enhanced and prolonged in Cd19/
mice (58% ± 8%, 48 hr, p < 0.05) as re-
ported (Watanabe et al., 2007). Despite
this, blood, spleen, and lymph node-
regulatory CD25+Foxp3+CD4+ T cell
numbers were identical in WT, hCD19Tg,
and Cd19/ mice (not shown). Thus,
enhanced or reduced B cell function in-
versely paralleled T cell-mediated inflam-
matory responses.
B Cell Depletion Enhances
CHS Responses
Whether B cells were directly responsible
for decreased T cell-mediated inflamma-
tory responses in hCD19Tg mice was determined by depleting
B cells in hCD19Tg mice with human CD19 mAb as described
(Yazawa et al., 2005). CD19mAbs depleted the majority of circu-
lating B cells within 1 hr of treatment, with > 95% depletion of
spleen and lymph node B cells within 2 days. Mice treated with
human CD19 mAb 7 days before primary sensitization showed
significantly enhanced CHS responses compared with control
mAb-treatedmice (p < 0.01, Figure 1B). Mice treated with human
CD19 mAb 2 days after primary oxazolone sensitization had
comparable CHS responses with control mAb-treated mice at
24 hr after oxazolone elicitation but developed augmented
CHS responses by 48 hr. Ear swelling 48 hr after oxazolone chal-
lenge in mice treated with human CD19 mAb 7 days before or
2 days after primary oxazolone sensitization was increased by
102% ± 8% or 89% ± 12%, respectively. Thus, B cell depletion
in hCD19Tg mice restored CHS responses to levels observed in
WT mice.
B cells were depleted frommicewith intact immune systems by
the useofCD20mAb toexaminewhether normalB cells regulate T
cell-mediated inflammation in WT mice. Mature spleen CD20+ B
cells in WT mice are eliminated within 2 days after a single CD20
mAb treatment (Uchida et al., 2004a). Mice depleted of B cells
7 days before or 2 days after primary oxazolone sensitization
exhibited significantly enhanced CHS responses when compared640 Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc.
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Unique CD1dhiCD5+ Regulatory B Cell SubsetFigure 2. IL-10 Production by Purified
Spleen B Cells from WT, hCD19Tg, and
Cd19/ Mice
(A) Representative flow-cytometry histograms
showing B cell purities after B220 mAb-coated
microbead isolation. (B) Luminex and (C) ELISA
determinations of IL-10 secretion by B220+ cells
cultured in media alone or containing LPS, or
CD40 mAb plus IgM antibody are shown (mean ±
SEM, nR 3). (D) IL-10-secreting B cell frequencies
determined by ELISPOT assay are shown. B220+
cells were incubated in the absence or presence
of LPS for 24 hr. Values represent mean numbers
(± SEM) of spot-forming cells per 105 B220+ cells
fromR three mice of each group.
(B–D) Significant differences between sample
means are indicated; *, p < 0.05; **, p < 0.01.
Results represent one of two independent experi-
ments producing similar results.with control mAb-treated mice: 91% ± 10% and 72% ± 11% in-
crease, respectively, at 48 hr after oxazolone challenge (p < 0.01,
Figure 1C). Thus, B cell depletion augmented T cell-mediated
inflammatory responses in both WT and hCD19Tg mice.
Whether CD19 deficiency completely eliminates B cell nega-
tive regulation was determined by depleting B cells from
Cd19/mice with CD20mAb. B cell depletion further increased
CHS severity in Cd19/mice, but the difference was not statis-
tically different from control mAb-treated mice (Figure 1D). This
suggests that some regulatory B cells still exist in Cd19/
mice, but at levels below those found in WT and hCD19Tg
mice. Moreover, anti-human CD19 as well as anti-mouse CD20
mAbs do not eliminate all peritoneal B cells (Hamaguchi et al.,
2005; Yazawa et al., 2005). Furthermore, CD20 mAb treatment
does not reduce serum or natural antibody levels (DiLillo et al.,
2008). Thereby, induced B cell depletion eliminates most B cell
negative regulation but does not eliminate the peritoneal B-1
cell population that also appears important for CHS initiation
(Itakura et al., 2005).
B Cell Cytokine Expression in WT, hCD19Tg,
and Cd19/ Mice
B cells produce multiple cytokines that influence immune
responses (Harris et al., 2000). Therefore, B cells from WT,
hCD19Tg, and Cd19/ mice were purified (>95% purities,
Figure 2A), with cytokine production quantified and compared
with T cell-mediated inflammatory responses observed in each
mouse line. Whereas B cells cultured without mitogens did not
produce cytokines, lipopolysaccharide (LPS)-stimulated B cells
fromWT, hCD19Tg, andCd19/mice produced tumor necrosis
factor-a, IL-1b, IL-10, and IL-6 protein as determined with Lumi-
nex assays (Figure 2B, not shown). IgM antibody plus CD40mAb
stimulation also induced the production of these cytokines, but
at lower amounts than LPS. Only WT B cells secreted transform-
ing growth factor-b1, but only at very low amounts after IgM
antibody plus CD40 mAb stimulation (not shown). Neither LPS
nor IgM antibody plus CD40mAb stimulation induced detectableIL-4, -5, -12, -13, -17, or -23 secretion (not shown). Nonetheless,
increased IL-10 production by hCD19Tg but reduced IL-10
production by Cd19/ B cells was the only cytokine change
that was inversely proportional to inflammatory responses in
these mice. In Luminex and standard ELISAs, B cells from
hCD19Tg mice showed increased IL-10 production compared
with WT mice (LPS stimulation, 1.8-fold; p < 0.01), whereas B
cells from Cd19/ mice exhibited reduced IL-10 production
(65%ofWT, p < 0.05; Figures 2B and 2C). With ELISPOT assays,
IL-10-producing B cell frequencies were 2.7-fold higher in
hCD19Tg mice than WT mice (p < 0.01) but 74% lower in
Cd19/ mice than in WT mice (p < 0.01; Figure 2D). Thus,
frequencies of IL-10-producing B cells were inversely propor-
tional to the inflammatory responses of hCD19Tg and CD19/
mice.
IL-10-Producing B Cells Localize in the Spleen
and Peritoneal Cavity
Reciprocal IL-10 production by B cells from hCD19Tg and
Cd19/ mice was verified directly by intracellular cytokine
staining. Cytoplasmic IL-10 production was not detected in rest-
ing B cells fromWT, hCD19Tg, orCd19/mice (Figure 3A). After
LPS, phorbol 12-myristate 13-acetate (PMA), and ionomycin
stimulation for 5 hr, the frequencies of spleen IL-10-producing
B cells was 7.4-fold higher in hCD19Tg mice than in WT mice
(p < 0.01), whereas the frequency of IL-10-producing B cells
was 85% lower in Cd19/ mice than in WT mice (p < 0.01;
Figure 3B). Interestingly, IL-10 production by non-B cells after
LPS, PMA, and ionomycin stimulation was also increased in
hCD19Tg mice (Figure S1 online). Peritoneal IL-10-producing B
cell frequencies were 3-fold higher in hCD19Tg mice than in
WT mice (p < 0.01) but 80% lower in Cd19/ mice (p < 0.01;
Figure 3C). Even though Cd19/ and hCD19Tg mice have
reduced numbers of splenic B cells compared with WT mice
(Haas et al., 2005), the numbers of IL-10-producing splenic
and peritoneal B cells were 2.1-fold- and 3.1-fold-higher in
hCD19Tg mice than in WT mice, respectively (p < 0.01). SplenicImmunity 28, 639–650, May 2008 ª2008 Elsevier Inc. 641
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Unique CD1dhiCD5+ Regulatory B Cell Subsetand peritoneal IL-10-producing B cell numbers were 80% and
78% lower in Cd19/ mice than in WT mice, respectively (p <
0.01). By contrast, naive or stimulated B cells from blood, periph-
eral andmesenteric lymph nodes, and Peyer’s patches exhibited
little, if any, IL-10 production in WT, hCD19Tg, or Cd19/ mice
(Figures 3D–3F, not shown). Intracellular staining of B cells from
Il10/ mice served as background controls. Thus, IL-10-pro-
ducing B cells represent a distinct subset that was dramatically
reduced in Cd19/ mice but preferentially expanded in
hCD19Tg mouse spleen and peritoneal cavity.
Figure 3. Cytokine Production by B Cells
from WT, hCD19Tg, and Cd19/ Mice
(A) Splenocytes without stimulation, or (B) spleen,
(C) peritoneal cavity, (D) blood, (E) peripheral
lymph node, and (F) mesenteric lymph node
lymphocytes after culture with LPS, PMA, ionomy-
cin, and monensin for 5 hr. B cells were stained
with B220 mAb and/or CD19 or CD20 mAbs. After
permeabilization, the cells were stained with IL-10
mAb. B220 staining was used as the initial gate for
identifying B cells (except peritoneal cavity). All
data are representative of three independent
experiments. Representative histograms for one
mouse show frequencies of IL-10-producing cells
among total B cells within the indicated gates. Bar
graphs indicate mean (± SEM) percentages and
numbers of B cells that produced IL-10 in one
representative experiment with three mice per
group. Significant differences between sample
means are indicated; **, p < 0.01.
Spleen IL-10-Producing B Cells
Are CD1dhiCD5+
Whether IL-10-producing B cells repre-
sent a known B cell subset was deter-
mined by immunofluorescence staining.
Because B cell cytoplasmic IL-10 was
only visualized after combined LPS,
PMA, ionomycin, andmonensin treatment
for 5 hr (Figure 3), the effect of this treat-
ment and cell permeabilization on pheno-
typeswasdetermined.Untreated, treated,
or permeabilized B cells from WT and
hCD19Tg mice expressed identical IgM,
IgD, CD19, CD5, CD1d, CD21, CD24,
CD23, CD11b, CD43, and B220 densities
(Figure 4A, not shown). These cell-surface
molecules were therefore used to catego-
rize IL-10-producingBcells. Spleen IL-10-
producing B cells in WT and hCD19Tg
micewerepart of aCD19hi subset (Figures
3B and 3C). Spleen IL-10-producing B
cells exhibited the CD5+CD19hi pheno-
type characteristic of B-1a cells, but they
unexpectedly expressed cell-surface
CD1d at high amounts in both WT and
hCD19Tg mice (Figure 4B). By contrast,
Cd19/ mice did not have detectable
spleen CD1dhiCD5+ or IL-10-producing B
cells (Figures 3B and 4C, Table 1). On average, B cells with
aCD1dhiCD5+ phenotype represented 2.3%and 12.2%of spleen
B220+ cells in WT and hCD19Tg mice, respectively (Figure 4C).
CD1dhiCD5+ splenic B cell numberswere 38%higher in hCD19Tg
mice than inWTmice (Table 1).Within theCD1dhiCD5+ B cell sub-
set, an average of 18% and 58% expressed IL-10 in WT and
hCD19Tgmice, respectively. CD1dloCD5+ B cells did not express
IL-10 (Figure 4C). When CD1dhiCD5+ or the remaining spleen B
cells were purified and then stimulated, the vast majority of
IL-10-producingBcellswere foundwithin theCD1dhiCD5+ subset642 Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc.
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Unique CD1dhiCD5+ Regulatory B Cell SubsetFigure 4. Phenotypes of IL-10-Producing B Cells
(A) CD1d and CD5 expression by CD19+ B220+ splenocytes fromWT and hCD19Tgmice does not change after LPS, PMA, ionomycin, andmonensin treatments.
CD1d and CD5 expression on CD19+B220+ cells before (thin line) or after 5 hr incubation with LPS, PMA, ionomycin, monensin, and permeabilization (thick line)
was determined by immunofluorescence staining.
(B) IL-10-producing spleen B cells from WT and hCD19Tg mice expressed both CD1d and CD5. Purified CD19+ splenocytes were cultured with LPS, PMA,
ionomycin, and monensin for 5 hr before permeabilization and staining with CD1d, CD5, B220, and IL-10 mAbs.
(C) Spleen IL-10-producing B cells represent a CD1dhiCD5+ subset distinct fromB-1a cells inWT and hCD19Tgmice. Histograms demonstrate cytoplasmic IL-10
expression by permeabilized CD1dhiCD5+, CD1dloCD5+, and CD1dloCD5B cells fromWT and hCD19Tgmice after LPS, PMA, and ionomycin stimulation. CD1d
and CD5 expression by B cells from Cd19/ and Il10/mice is also shown. Percentages indicate mean (± SEM) CD1dhiCD5+ or IL-10+ cell frequencies among
CD1dhiCD5+ B cells as indicated for each group of three mice.
(D) In vitro stimulation does not induce the CD1dhiCD5+ phenotype of IL-10-secreting B cells. Splenic CD1dhiCD5+ or CD1dloCD5Bcells were purified from three
WT or hCD19Tg mice by cell sorting and pooled before LPS, PMA, and ionomycin stimulation for 5 hr, with subsequent assessment for cytoplasmic IL-10
production by immunofluorescence staining. Percentages indicate IL-10+ cell frequencies.
(E) Cell-surface molecule expression by IL-10+ (thick line) or IL-10 (dashed line) B cells fromWT and hCD19Tgmice. CD19+ splenocytes or peritoneal cells were
culturedwithLPS,PMA, ionomycin, andmonensin for 5hrbeforepermeabilizationandstaining for IL-10. Thin lines represent isotype-matchedcontrolmAbstaining.
All results representR two independent experiments with three mice in each group.of B cells fromWT and hCD19Tgmice (Figure 4D), further exclud-
ing the possibility that LPS, PMA, and ionomycin treatment
induced their phenotype. Whether the CD1dhiCD5+ B cell pheno-
type was induced by oxazolone sensitization in vivo was alsoassessed. B cell CD1d and CD5 expression and CD1dhiCD5+ B
cell numbers were similar in oxazolone sensitized and naive WT
mice (Figure S2), making it unlikely that the CD1dhiCD5+ B pheno-
type was induced by oxazolone sensitization.Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc. 643
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Unique CD1dhiCD5+ Regulatory B Cell SubsetThe phenotype of IL-10-producing spleen B cells was further
verified by determining the phenotypes of IL-10+ and IL-10 pop-
ulations. Most splenic IL-10-producing B cells expressed IgM,
CD1d, CD19, and CD24 at high levels (Figures 4B and 4E, not
shown). Approximately half of splenic IL-10-producing B cells
expressed high-density CD21 (44.3% ± 2.6% and 54.8% ±
1.6% in WT and hCD19Tg mice, respectively). Peritoneal IL-10-
producing B cells were CD19hiIgMhiIgDloCD5+CD23CD11b+
CD43+B220lo, a phenotype shared by B-1a cells. Thus, splenic
IL-10-producing B cells shared features common to marginal
zone (MZ), T2-MZ precursor, and B-1a B cells but were localized
within a unique CD1dhiCD5+ subset.
Increased B Cell IL-10 Expression during Inflammation
Whether B cell IL-10 production might regulate T cell-mediated
inflammationwasdeterminedby assessment of IL-10 production
by B cells during CHS responses in WT, hCD19Tg, and Cd19/
mice.Spleenanddrainingaxillary and inguinal lymphnodeBcells
were purified 2 days after ear challenge with oxazolone, with
IL-10mRNAexpressionquantifiedby real-timepolymerase chain
reaction (PCR). Relative IL-10 transcripts in B cells from spleen
and peripheral lymph nodes of unchallenged hCD19Tg mice
were significantly increased relative to B cells from WT mice
(spleen4.5-fold,p<0.01, lymphnode1.5-fold,p<0.05;Figure5A).
Table 1. Spleen B Cell Subsets in Wild-Type, hCD19Tg, Cd19/,
and Il10/ Mice
B Cell Subset Numbers (3 105)
Mouse Genotype CD1dhiCD5+ B-1a MZ Follicular
hCD19Tg 18 ± 2* 32 ± 4 16 ± 1** 68 ± 4*
Wild-type 13 ± 1 30 ± 3 42 ± 3 362 ± 42
Il10/ 12 ± 1 31 ± 2 42 ± 1 324 ± 17
Cd19/ 0.4 ± 0.1** 8 ± 1** 12 ± 1** 148 ± 6*
B cell subsets were as follows: CD1dhiCD5+, B-1a (CD5+B220lo), MZ
(CD1dhiCD21hiB220hi), and follicular (CD21intCD23+B220hi). Values
(± SEM, n R 4 mice) were significantly different from those of wild type
mice; *, p < 0.05; **, p < 0.01.
Figure 5. IL-10 Production by CD1dhiCD5+ B
Cells Correlates with Suppression of T Cell-
Mediated Inflammation
(A) IL-10productionbyWT,hCD19Tg,andCd19/
B cells during CHS responses. B220+ cells were
purified from the spleen and draining lymph nodes
of naivemice (filled bars) or 2 days following oxazo-
lone challenge (open bars).
(B) Splenic CD1dhiCD5+ or non-CD1dhiCD5+ B
cells were purified from naive or oxazolone-
challenged WT mice (as in A) by cell sorting.
(A and B) Values represent mean ratios of IL-10
transcripts normalized to GAPDH transcript levels
(± SEM) in triplicate samples of pooled RNA from
three mice as quantified by real-time PCR. Results
are representative of at least two independent
experiments with three mice in each group. Sig-
nificant differences between sample means are
indicated; *, p < 0.05; **, p < 0.01.
(C) IL-10 production by circulating B cells fromWT
mice during CHS responses. Blood mononuclear
cells from three mice were pooled and cultured
with LPS, PMA, ionomycin, and monensin for 5 hr
before staining with B220 and/or CD19 or CD20
mAbs. Values represent the percentage of IL-10-
producing cells among total B cells with results
from Il10/mice shown as a control.
(D) CHS responses in hCD19Tg mice treated with
control or IL-10 receptor-specific mAb 1 hr before
and 47 hr after oxazolone challenge.
(E) CHS responses in WT and Il10/ mice after B
cell depletion. Mice were treated with CD20 or
control mAb 7 days before the first sensitization
with oxazolone (mean ± SEM, n R 4). Significant
differences between the mean CHS responses
between groups and control mAb-treated WT
mice are indicated; *, p < 0.05; **, p < 0.01.644 Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc.
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Unique CD1dhiCD5+ Regulatory B Cell SubsetDuringCHS responses, spleenBcells frombothWTandhCD19Tg
mice expressed more IL-10 transcripts than naive B cells (6-fold,
p < 0.01 and 2.2-fold, p < 0.01, respectively), and hCD19TgB cells
produced higher IL-10 transcripts than WT B cells (1.8-fold, p <
0.01; Figure 5A, left panel). IL-10 transcripts in spleen B cells
from challenged Cd19/ mice increased significantly during
CHS responses, but only up to 16% of the amount seen in WT B
cells (p<0.01). Bycontrast, Bcell IL-10mRNAexpression indrain-
ing lymph nodes did not change during CHS response (Figure 5A,
right panel). In similar experiments, IL-10 transcripts produced by
the spleenCD1dhiCD5+ B cell subsetwere increased 7.1-fold dur-
ing CHS responses in comparisonwith naive CD1dhiCD5+ B cells,
whereas IL-10 transcripts were lower in non-CD1dhiCD5+ B cells
with or without sensitization and challenge (Figure 5B). Thus, B
cell IL-10 production in the spleen but not lymph nodes was
increased during CHS responses, with the amount of IL-10 pro-
duction byB cells being inversely proportional to the severity of in-
flammatory responses.
IL-10 production by blood B cells was assessed to determine
whether IL-10-producing B cells enter the circulation during
CHS responses. IL-10-producing B cells were not observed in
Il10/ or naive mice before oxazolone sensitization (Figures 3D
and5C).However, circulating IL-10-producingBcellswere found
in the blood after sensitization, with the percentage of circulating
IL-10-producing B cells peaking before challenge and gradually
decreasing after challenge (Figure 5C). Thus, IL-10-producing
B cells enter the circulation during CHS responses.
IL-10 Inhibits T Cell-Mediated Inflammatory Responses
in hCD19Tg and WT Mice
Blocking IL-10 function in vivo with an IL-10 receptor-specific
mAb enhances CHS responses in WT mice (Ferguson et al.,
1994). Therefore, whether the enhanced CHS responses
observed in hCD19Tg mice were dependent on IL-10 was
assessed with a function-blocking mAb against the IL-10 recep-
tor. Blocking IL-10 receptor function 1 hr before oxazolone chal-
lenge significantly augmented CHS responses in hCD19Tg mice
when compared with control mAb-treated mice (Figure 5D, p <
0.05 at 48 hr). In fact, blocking IL-10 receptor function restored
CHS responses to the degree normally observed in WT mice.
Thus, the suppression of T cell-mediated inflammation observed
in hCD19Tg mice was IL-10 dependent.
The relative contribution ofWT IL-10-producing B cells to CHS
suppressionwas assessed by comparison of the effects of CD20
mAb-induced B cell depletion in WT and Il10/ mice. B cell
depletion significantly augmented CHS responses in WT mice
(Figure 5E). Remarkably, CHS responses were increased
similarly by B cell depletion and IL-10 deficiency 24 hr after chal-
lenge. Subsequently, CHS responses were higher in Il10/
mice, suggesting that B cell IL-10 production contributed most
substantially to early inhibition of CHS responses, whereas
IL-10 production by the remaining peritoneal B cells or other
IL-10-producing subsets regulated later stages of the CHS
response. Equally important was that B cell depletion did not
affect CHS severity in Il10/ mice, arguing that the inhibitory
role of B cells in CHS regulation in WT mice is due to IL-10
production. Thus, B cells suppressed T cell-mediated inflamma-
tion in an IL-10-dependent manner, with a more substantial
contribution during early inflammation.CD1dhiCD5+ B Cells Inhibit Inflammatory Responses
The ability of CD1dhiCD5+ B cells to regulate CHS responses
was assessed with adoptive-transfer experiments. Spleen
CD1dhiCD5+ B cells and non-CD1dhiCD5+ B cells were purified
from either oxazolone-sensitized (5 days after primary sensitiza-
tion) or unsensitized WT mice (Figure 6A, left panels). Purified B
cells were then transferred into oxazolone-sensitized Cd19/
mice that were challenged with oxazolone 48 hr after the trans-
fer. Transferring CD1dhiCD5+ B cells into Cd19/ mice signifi-
cantly reduced (43% at 48 hr, p < 0.05) ear swelling (Figure 6A,
middle panel). Ear swelling was not inhibited in recipients
given CD1dhiCD5+ B cells from nonsensitized mice or non-
CD1dhiCD5+ B cells from sensitized mice. Likewise, splenic
CD1dhiCD5+ B cells purified from oxazolone-sensitized Il10/
mice did not affect ear swelling in Cd19/ recipients (Figure 6A,
right panel). Thus, sensitized splenic CD1dhiCD5+ B cells in-
hibited CHS responses in an IL-10-dependent manner.
Transfer of naive WT CD1dhiCD5+ B cells into Cd19/mice 2
days before sensitization allowed sufficient time for the Cd19/
mice to develop alloantigen-specific immune response against
the cell-surface CD19 antigen that is abundantly expressed on
WT B cells. Therefore, whether the transfer of IL-10-producing
CD1dhiCD5+ B cells before sensitization and before challenge
played a role in CHS responses in WT mice was assessed.
Spleen CD1dhiCD5+ B cells were purified from oxazolone-sensi-
tizedCD20-deficient mice (Figure 6B, left panels) and transferred
intoWT recipients that were depleted of B cells usingCD20mAb.
CD20-deficient mice had normal numbers of CD1dhiCD5+ IL-10-
producing B cells compared to WT mice, and CD20-deficient
B cells were not depleted by CD20 mAb (not shown). When B
cells were depleted inWTmice, CHS responses were increased.
However, the adoptive transfer of sensitized CD1dhiCD5+ CD20-
deficient B cells just before challenge normalized CHS re-
sponses in B cell-depleted mice (Figure 6B, middle panel). The
adoptive transfer of naive CD1dhiCD5+ CD20-deficient B cells
into B cell-depleted mice 2 days before oxazolone sensitization
also normalized subsequent CHS responses in B cell-depleted
mice (Figure 6B, right panel). The transfer of non-CD1dhiCD5+
CD20-deficient B cells from naive or sensitized mice into recipi-
ents before sensitization or challenge, respectively, did not re-
duce oxazolone-induced ear swelling. Thus, IL-10 secretion by
CD1dhiCD5+ B cells regulated T cell-mediated inflammation
in vivo.
Whether IL-10 secretion by CD1dhiCD5+ B cells was antigen
specific was addressed by the adoptive transfer of splenic
CD1dhiCD5+ B cells purified from 2,4-dinitrofluorobenzene
(DNFB)-sensitized mice (Figure 6C, left panels). When trans-
ferred into oxazolone-sensitized Cd19/ recipients, neither
CD1dhiCD5+ nor non-CD1dhiCD5+ B cells purified from DNFB-
sensitized mice affected ear swelling in oxazolone-challenged
Cd19/ recipients (Figure 6C, right panel). These findings sug-
gest that IL-10-producing CD1dhiCD5+ B cell function is antigen
specific rather than a result of inflammatory stimuli.
DISCUSSION
This study demonstrates that a phenotypically distinct
CD1dhiCD5+CD19hi B cell subset regulates T cell-mediated in-
flammatory responses through IL-10 secretion. For convenience,Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc. 645
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as ‘‘B10 cells.’’ These rare IL-10-producing B cells represented
only 1%–2% of spleen B220+ cells and 7%–8% of peritoneal
B cells in WT mice but were not normally detectable in blood or
lymph nodes. B10 cell numbers were expanded substantially
in the spleen (10% of B220+ cells) and peritoneal cavity
(25%) but not blood or lymph nodes of hCD19Tg mice, and
they were rare in Cd19/ mice. Likewise, the abilities of B cells
from hCD19Tg, WT, and Cd19/mice to inhibit CHS responses
paralleled their capacity to secrete IL-10. Spleen and bloodB cell
IL-10 expression was also enhanced in WT and hCD19Tg mice
during CHS responses, but not in Cd19/ mice. Furthermore,
blocking IL-10 receptor function normalized CHS responses in
hCD19Tg mice. The adoptive transfer of spleen CD1dhiCD5+ B
cells from WT and CD20-deficient mice normalized CHS
Figure 6. CD1dhiCD5+ B Cells Inhibit T Cell-
Mediated Inflammation
(A) Splenic CD1dhiCD5+ or non-CD1dhiCD5+ B
cells from oxazolone-sensitized or naive mice
were purified (representative results, left panel).
Purified cells from WT (middle panel) or Il10/
(right panel) mice were transferred into oxazo-
lone-sensitized Cd19/ mice. Recipient mice
were challenged 48 hr after transfer with increased
ear thickness measured. Significant differences
between PBS-treated mice versus other groups
are indicated; *, p < 0.05.
(B) CD1dhiCD5+ or non-CD1dhiCD5+ splenic B
cells were purified from sensitized or naive
CD20-deficient mice and transferred into sensi-
tized (middle panel) or naive WT (right panel)
mice that had been treated with CD20 or control
mAb 7 days earlier as in (A). For sensitized mice,
the transfer was performed 2 days before chal-
lenge (middle panel). For naive mice, the transfer
was performed 2 days before sensitization (right
panel). Significant differences between CD20
mAb-treated mice versus other groups are indi-
cated; *, p < 0.05; **, p < 0.01.
(C) Adoptive transfer of CD1dhiCD5+ or non-
CD1dhiCD5+ B cells purified from DNFB-sensi-
tized mice does not alter oxazolone-induced
CHS responses in Cd19/ recipients. The same
experimental protocol was used as in (A), except
that adoptively transferred B cells were purified
from DNFB-sensitized WT mice.
Values represent means (± SEM) fromR four mice
of each group.
responses in Cd19/ mice and CD20
mAb-treated mice, respectively, whereas
spleen CD1dhiCD5+ B cells from
Il10/ mice were without effect. Thus,
CD1dhiCD5+Bcellproductionof IL-10 reg-
ulated T cell-dependent CHS responses.
The existence of B10 cells explains
increased CHS responses in WT mice
depleted of B cells and in Cd19/
mice that were deficient in B10 cells.
Likewise, the increase in B10 cell num-
bers in hCD19Tg mice explains their
modest CHS responses. That B cell depletion in Cd19/
mice did not reduce CHS severity excludes the possibility that
Cd19/ B cells abnormally produce proinflammatory media-
tors during CHS responses. Similarly, B cell depletion increased
CHS responses in WT mice to the degree observed in Cd19/
mice, arguing that B10 cells were directly involved in regulating
the magnitude of CHS responses. However, B cell depletion or
blocking IL-10 receptor function normalized CHS responses in
hCD19Tg mice but did not induce CHS responses to the degree
observed in Cd19/ mice. IL-10 production by non-B cells
was increased in hCD19Tg mice but decreased in Cd19/
mice. In addition, hCD19Tg mice have developmental abnor-
malities within their immune systems as a result of congenital
CD19 overexpression and hyperresponsive B cells, including
abnormal B-1 subset development (Haas et al., 2005),646 Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc.
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1996), and alterations within their T cell compartments. Thus,
cell types in addition to B10 cells may also regulate CHS re-
sponses, particularly in hCD19Tg mice.
That B10 cells were found exclusively within the relatively rare
spleen CD1dhiCD5+CD19hi B cell subset distinguishes the cur-
rent results from previous studies (Mizoguchi and Bhan, 2006)
but also unifies most of the current studies regarding IL-10 pro-
duction by B cells. Some spleen B cells and peritoneal CD5+
B-1a cells are known to produce IL-10 (Brummel and Lenert,
2005; Evans et al., 2007; Fillatreau et al., 2002; Harris et al.,
2000; Mauri et al., 2003; Spencer and Daynes, 1997). Specifi-
cally, spleen B cells with a CD21+CD23 MZ phenotype can
produce IL-10 in response to CpG (Brummel and Lenert, 2005)
stimulation. Spleen CD1d+CD21+CD23+ B cells with a T2-MZ
precursor phenotype also produce IL-10 and can inhibit colla-
gen-induced arthritis (Evans et al., 2007). Spleen CD5+ B cells
also produce IL-10 after IL-12 stimulation, whereas CD5 B cells
do not (Spencer andDaynes, 1997). Thus, spleen B10 cells share
some phenotypic markers with both CD1dhiCD21hi MZ B cells
and CD5+CD19hiB220lo B-1a cells. However, the frequency of
spleen CD1dhiCD5+ B cells inWTmice (2.3%± 0.1%) was signif-
icantly lower than the frequencies of spleen B-1a (6.2% ± 0.3%,
p < 0.01) and MZ (6.9% ± 0.4%, p < 0.01) B cells. IL-10 secretion
was predominantly localized within the spleen CD1dhiCD5+ B
cell subset in WT mice, whereas other spleen B cells including
B-1a and follicular B cells did not secrete IL-10. Because frac-
tionating such small B cell subsets with absolute purity is techni-
cally difficult, it is possible that some IL-10-producing B cells
exist that are not CD1dhiCD5+, although these cells may also
represent B10 cells at different states of maturation. Alterna-
tively, it is possible that B10 cells may represent an activated
MZ or B-1a subset, although B10 cells did not selectively
produce other cytokines (our unpublished data). Thus, the B10
spleen subset as currently identified represents a relatively rare
but functionally potent population of regulatory B cells.
IL-10 production probably explains the potent ability of B10
cells to regulate T cell-mediated inflammatory responses. The
adoptive transfer of 2 3 106 WT CD1dhiCD5+ B cells normalized
the CHS responses of both Cd19/ mice and mice depleted of
B cells. This is remarkable given that not all CD1dhiCD5+ B cells
produced IL-10 after LPS stimulation. Moreover, B10 cells may
be antigen specific because the adoptive transfer of
CD1dhiCD5+ B cells from antigen-sensitized mice into Cd19/
recipients inhibited CHS responses, and CD1dhiCD5+ B cells
from unsensitized mice or from mice sensitized with a different
antigen were without effect. It is not known whether splenic or
peritoneal IL-10-producing B cells affect immune responses
centrally or whether this depends on B10 cell migration into
draining lymph nodes or peripheral tissues. However, IL-10 tran-
scripts were not increased in B cells from lymph nodes draining
the sites of antigen challenge. Furthermore, B cell infiltration is
not observed in the challenged ears of WT and Cd19/ mice
during CHS responses (Watanabe et al., 2007). Nonetheless,
IL-10-producing B cells were found in the circulation during
CHS responses andmay thereby migrate in small numbers to lo-
cal sites of inflammation. B cell depletion in tight-skin mice,
a model for human systemic sclerosis, reduces IL-10, IL-4, IL-
6, and transforming growth factor-b production in the skin,whereas B cell transcripts are not found in the lesional skin (Ha-
segawa et al., 2006). Similarly, B cell-deficient andCd19/mice
have augmented EAE responses (Fillatreau et al., 2002; Mat-
sushita et al., 2006), although CNS B cells are rare during EAE
(McGeachy et al., 2005). Thus, splenic and peritoneal IL-10-pro-
ducing B cells may alter the peripheral production of IL-10 and
other cytokines by non-B cells circulating through draining
lymph nodes or peripheral tissue, thereby influencing systemic
and local inflammatory responses.
Functional and lineage relationships among spleen B10, B-1a,
and MZ B cells and peritoneal B-1a, B-1b, and peritoneal IL-10-
producing B cells are possible. However, their only common
features identified thus far are shared phenotypicmarkers. Given
that B10 and B-1a cell frequencies are increased in hCD19Tg
mice, and B10 and B-1a cells in Cd19/ mice are rare (Haas
et al., 2005; Sato et al., 1996), it is possible that B10 cells and
B-1a cells represent different branches of a common lineage.
By contrast, B-1b cell frequencies are increased in Cd19/
mice (Haas et al., 2005). Phenotypically and histologically
defined MZ B cells are also reduced in Cd19/ mice, whereas
organizedMZs are difficult to identify in hCD19Tgmice by immu-
nohistochemistry staining (Haas et al., 2005). Likewise, spleen
B cells with a CD1dhiCD21hiB220+ MZ phenotype were reduced
in hCD19Tg mice, and CD1dhiCD5+ B cells numbers were
increased relative toWTmice.Moreover, only50%of B10 cells
exhibited the CD21hi phenotype of MZ B cells. Nonetheless, in-
creased numbers of splenic IL-10-producing B cells and an
expanded population of MZ-like CD1dhi B cells that express
CD5 have been identified in mouse lupus models (Duan et al.,
2007). Thus, B10 cells may regulate autoimmune disease
because hCD19Tg mice develop autoimmunity with age (Sato
et al., 1996). Notably, IL-10 production was not required for
CD1dhiCD5+ B cell generation because this subset was present
in Il10/mice. Regardless, it is exciting to speculate that each B
cell subset has different functions, with B10 cells producing
IL-10 and regulating T cell function, whereas B-1a cells produce
natural and autoantibodies, B-1b cells produce adaptive im-
mune responses to T cell-independent antigens (Haas et al.,
2005), and MZ B cells provide protection early during pathogen
challenge (Martin et al., 2001).
B cell depletion in mice resulted in enhanced CHS responses,
suggesting that B10 cells regulate T cell responses. B cell deple-
tion also significantly delays the onset of collagen-induced
arthritis in DBA/1J mice (Yanaba et al., 2007), skin sclerosis in
tight-skin mice (Hasegawa et al., 2006), and diabetes in nonob-
ese diabetic mice (Xiu et al., 2008). By contrast, B cell depletion
early in the course of disease worsens EAE, whereas B cell
depletion at the height of disease ameliorates EAE (our unpub-
lished data). This suggests the dominance of different B cell
functions, including B10 cell function, during disease progres-
sion. Similarly, B cell depletion in humans with Rituximab, a
chimeric human CD20 mAb, was recently found to exacerbate
ulcerative colitis (Goetz et al., 2007) and may induce psoroasis
development (Dass et al., 2007). By contrast, B cell depletion
with Rituximab may benefit rheumatoid arthritis, systemic lupus
erythematosus, and multiple sclerosis patients (Edwards and
Cambridge, 2006; Hauser et al., 2008). Thus, the benefit of B
cell-depletion therapy is likely to vary according to disease and
the relative involvement of different B and T cell subsets.Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc. 647
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the rare IL-10-producing CD1dhiCD5+ B10 cell subset in this
study may lead to the identification of B10 cells in humans that
similarly regulate inflammatory responses. Further defining the
role of B10 cells and other B cell subsets in disease and regula-
tory function in vivo may provide new insights and therapeutic
approaches for treating inflammatory and organ-specific auto-
immunity in addition to other diseases.
EXPERIMENTAL PROCEDURES
Mice and Immunotherapy
WT C57BL/6 and Il10/ (B6.129P2-Il10tmlCgn/J) mice (Kuhn et al., 1993) were
from the Jackson Laboratory (Bar Harbor, ME). CD20-deficient, Cd19/, and
human CD19Tg (h19-1 line) mice were as described (Sato et al., 1996, 1997;
Uchida et al., 2004b). Specifically, Cd19/ and hCD19Tg mice were back-
crossed with C57BL/6 mice for 14 and seven generations, respectively.
B cells were depleted with sterile CD20 and human CD19 mAbs (250 mg) or
isotype-matched control mAbs (250 mg) injected in 200 ml PBS through lateral
tail veins. All mice were bred in a specific pathogen-free barrier facility and
used at 8–12 weeks of age. The Duke University Animal Care and Use
Committee approved all studies.
Abs and Immunofluorescence Analysis
Mouse CD20-specific mouse mAb MB20-11 (IgG2c) was used as described
(Uchida et al., 2004b). The mouse anti-human CD19 (hCD19) mAb FMC63
(IgG2a, provided by Dr. Heddy Zola, Child Health Research Institute, Adelaide,
South Australia) was used as described (Yazawa et al., 2005). Other mAbs
included the following: B220 mAb RA3-6B2 (provided by Dr. Robert Coffman,
DNAX Corp., Palo Alto, CA); CD19 (1D3), CD5 (53-7.3), CD1d (1B1), CD21/35
(7G6), CD23 (B3B4), CD24 (M1/69), CD25 (PC61), CD43 (S7), and CD11b (M1/
70) (from BD PharMingen, San Diego, CA); IgM (11/41) (from eBioscience, San
Diego, CA); and IgD (11-26) (from Southern Biotechnology Associates, Bir-
mingham, AL). Intracellular staining for Foxp3 (FJK-16 s, eBioscience) used
the Cytofix/Cytoperm kit (BD PharMingen). Single-cell suspensions of spleen,
peripheral lymph node (cervical, paired axillary, and inguinal), and mesenteric
lymph node were generated by gentle dissection. Peritoneal-cavity leukocytes
were isolated with 10 ml of cold (4C) PBS injected into the peritoneum of sac-
rificed mice followed by gentle massage of the abdomen. Intestinal Peyer’s
patches were isolated as described (Venturi et al., 2003). Peripheral blood
mononuclear cells were isolated from heparinized blood after centrifugation
over a discontinuous Lymphoprep (Axis-Shield PoCAs,Oslo, Norway) gradient.
Viable cells were counted with a hemocytometer, with relative lymphocyte
percentages determined by flow-cytometry analysis. Single-cell leukocyte
suspensions were stained on ice with predetermined optimal concentrations
of each antibody for 20–60 min and fixed as described (Sato et al., 1996). Cells
with the light-scatter properties of lymphocytes were analyzed by 2–4-color
immunofluorescence staining and FACScan or FACSCalibur flow cytometers
(Becton Dickinson, San Jose, CA). Background staining was determined
with unreactive isotype-matched control mAbs (Caltag Laboratories, San
Francisco, CA) with gates positioned to excludeR 98% of unreactive cells.
Contact Hypersensitivity Reaction
CHS reactionswere inducedwith oxazolone as described (Tedder et al., 1995).
In brief, mice were sensitized with 25 ml of oxazolone (100 mg/ml, Sigma, St.
Louis, MO) in acetone/olive oil (4:1 v/v) applied evenly for 2 consecutive
days on a shaved hind flank. On day 5, sensitized mice were challenged by
application of 10 ml of oxazolone solution (10 mg/ml) in acetone/olive oil (4:1)
to the right ear (5 ml on the dorsal side and 5 ml on the ventral side). In certain
experiments, 25 ml of 0.5%DNFB (Sigma) in acetone/olive oil (4:1) was used as
the sensitization agent. An identical amount of acetone/olive oil (4:1) was
administered to the left ear. In some experiments, mice were treated with
IL-10 receptor (1B1.3a; BD PharMingen) or control mAb (250 mg) 1 hr before
and 47 hr after oxazolone challenge. The thickness of the central portion of
each ear lobewasmeasured at 24, 48, 72, and 96 hr after challenge with a con-
stant-force, calibrated digital thickness gage (Mitsutoyo Corp., Tokyo, Japan).648 Immunity 28, 639–650, May 2008 ª2008 Elsevier Inc.Each ear lobe was measured three times at each time interval in a blinded
fashion, with the mean of these values used for analysis.
B Cell Isolation and Stimulation
B220 mAb- or CD19 mAb-coated microbeads (Miltenyi Biotech, Auburn, CA)
were used to purify B cells by positive selection following the manufacturer’s
instructions. For cytokine production, 4 3 105 purified B cells were cultured
either with LPS (10 mg/ml, Escherichia coli serotype 0111: B4, Sigma) or with
mouse IgM-specific goat F(ab’)2 antibody (20 mg/ml, Cappel, Aurora, OH)
plus CD40 mAb (1 mg/ml, HM40-3; BD PharMingen) in 0.2 ml of complete
medium in a 96-well flat-bottom plate for 48 hr. Culture supernatant fluid
was collected after 48 hr to assess cytokine production.
Flow Cytometric Analysis of Intracellular IL-10 Synthesis
In brief, isolated leukocytes or purified cells were resuspended (1 3 106 cells/
ml) with LPS (10 mg/ml), PMA (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma),
and monensin (2 mM; eBioscience) for 5 hr. For IL-10 detection, Fc receptors
were blocked with mouse Fc receptor-specific mAb (2.4G2; BD PharMingen)
before cell-surface staining and then fixed and permeabilized with the Cytofix/
Cytoperm kit (BD PharMingen) according to the manufacturer’s instructions.
Permeabilized cells were stained with phycoerythrin-conjugated IL-10 mAb
(JES5-16E3; BD PharMingen). Leukocytes from Il10/ mice served as nega-
tive control to demonstrate specificity and background-staining levels.
Cell Sorting and Adoptive Transfers
Splenic B cells were purified with CD19 mAb-coupled microbeads (Miltenyi
Biotech). In addition, CD1dhiCD5+ B cells were selected with a FACSVantage
SE flow cytometer (Becton Dickinson) with purities of 85%–95%. After
isolation, 2 3 106 CD1dhiCD5+ or non-CD1dhiCD5+ B cells were transferred
intravenously into Cd19/ or B cell-depleted recipient mice before CHS
induction.
Statistical Analysis
All data are shown as mean ± standard error of the mean (SEM). The signifi-
cance of differences between sample means was determined with the
Student’s t test.
SUPPLEMENTAL DATA
Additional Experimental Procedures and two figures are available at http://
www.immunity.com/cgi/content/full/28/5/639/DC1/.
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